Trials / Recruiting
RecruitingNCT04278131
BS01 in Patients With Retinitis Pigmentosa
Phase 1/2, Safety and Efficacy Trial of BS01, a Recombinant Adeno-Associated Virus Vector Expressing ChronosFP in Patients With Retinitis Pigmentosa
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Bionic Sight LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Phase 1/2, Safety and Efficacy Trial of BS01, a Recombinant Adeno-Associated Virus Vector Expressing ChronosFP (AAV2-CAG-ChronosFP) in Patients with Retinitis Pigmentosa
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BS01 | Non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector expressing an enhanced light-sensitive channelrhodopsin gene (ChronosFP) |
Timeline
- Start date
- 2020-02-06
- Primary completion
- 2026-12-30
- Completion
- 2029-12-30
- First posted
- 2020-02-20
- Last updated
- 2026-01-23
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04278131. Inclusion in this directory is not an endorsement.